Wiggs Janey L, Langgurth Anne M, Allen Keri F
Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston Massachusetts.
Trans Am Ophthalmol Soc. 2014 Jul;112:94-102.
CYP1B1 mutations cause autosomal recessive congenital glaucoma. Disease risk assessment for families with CYP1B1 mutations requires knowledge of the population mutation carrier frequency. The purpose of this study is to determine the CYP1B1 mutation carrier frequency in clinically normal individuals residing in the United States. Because CYP1B1 mutations can exhibit variable expressivity, we hypothesize that the mutation carrier frequency is higher than expected.
Two hundred fifty individuals without glaucoma or a family history of glaucoma were enrolled. CYP1B1 mutations were identified by DNA sequencing, and pathogenicity was estimated by PolyPhen-2 or a previous report of disease causality.
Based on the disease frequency (1 in 10,000) and prevalence of CYP1B1-related congenital glaucoma (15% to 20%), the frequency of CYP1B1-related congenital glaucoma in the United States is approximately 1 in 50,000. Assuming Hardy-Weinberg equilibrium, the expected CYP1B1 mutation carrier frequency would be 1 in 112, or 0.89%. Among the 250 study participants, 11 (4.4%) are carriers of a single pathogenic mutation, representing a carrier frequency of 1 in 22, which is 5.1 times the expected frequency. A higher-than-expected carrier frequency (1 in 33, 3.0%) was also observed in 4300 white individuals sequenced by the National Heart Lung and Blood Institute Exome Sequencing Project.
Our results show that the CYP1B1 mutation carrier frequency in the US population is between 1 in 22 and 1 in 33, which is 5.1 to 3.4 times the expected frequency. These results suggest that more individuals than expected are carriers of a deleterious CYP1B1 mutation, and that the prevalence of CYP1B1-related disease may be higher than expected.
CYP1B1基因突变会导致常染色体隐性遗传性先天性青光眼。对携带CYP1B1基因突变的家庭进行疾病风险评估需要了解人群中该突变携带者的频率。本研究的目的是确定居住在美国的临床正常个体中CYP1B1基因突变携带者的频率。由于CYP1B1基因突变可能表现出可变的表达性,我们推测该突变携带者的频率高于预期。
招募了250名既无青光眼也无青光眼家族史的个体。通过DNA测序鉴定CYP1B1基因突变,并通过PolyPhen-2或先前关于疾病因果关系的报告评估其致病性。
根据疾病发生率(万分之一)和CYP1B1相关先天性青光眼的患病率(15%至20%),美国CYP1B1相关先天性青光眼的发生率约为五万分之一。假设符合哈迪-温伯格平衡,预期的CYP1B1基因突变携带者频率应为1/112,即0.89%。在250名研究参与者中,11人(4.4%)是单一致病性突变的携带者,携带者频率为1/22,是预期频率的5.1倍。在美国国立心肺血液研究所外显子测序项目测序的4300名白人个体中,也观察到高于预期的携带者频率(1/33,3.0%)。
我们的结果表明,美国人群中CYP1B1基因突变携带者的频率在1/22至1/33之间,是预期频率的5.1至3.4倍。这些结果表明,携带有害CYP1B1基因突变的个体比预期的更多,并且CYP1B1相关疾病的患病率可能高于预期。